In human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, Trastuzumab deruxtecan (see Figure 1) was used as a monotherapy and was found to stimulate the activation of NK cells against HER2. This evidence concerns the gene ERBB2 and breast cancer.